Dissecting follicular lymphoma: high versus low risk

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Follicular lymphoma (FL) management has advanced, improving patient survival rates.
• Significant heterogeneity exists within FL, leading to aggressive disease and transformation in some patients.
• Current prognostic indices are primarily for frontline treatment and do not fully capture disease complexity.

Purpose of the Study:

• To review the current knowledge on risk stratification in follicular lymphoma.
• To identify unmet needs in prognostic tools, especially for relapsed and refractory FL.
• To discuss the importance of patient heterogeneity in influencing management and prognosis.

Main Methods:

• Literature review of current prognostic tools and risk stratification strategies in FL.
• Analysis of limitations of existing indices like FLIPI and FLIPI-2.
• Discussion of factors influencing prognosis, including prior therapy and biologic data.

Main Results:

• Most patients with follicular lymphoma (FL) survive over a decade, but disease heterogeneity impacts outcomes.
• Existing prognostic tools (e.g., FLIPI, FLIPI-2) are mainly for frontline settings, with a need for tools in relapsed/refractory disease.
• Duration of response and prior therapy type are crucial in relapsed/refractory FL, and biologic data integration is lacking.

Conclusions:

• Risk stratification in FL is critical due to disease heterogeneity and varying treatment responses.
• There is a need for validated prognostic tools for relapsed/refractory FL that incorporate biologic insights.
• Understanding sources of heterogeneity is key for optimizing management, surveillance, and prognosis in FL.